NewsEvents

Your Yourlocation: Home > Inhaled steroids combined with tiotropium bromide(136310-93-5) in the treatment of asthma

Tiotropium bromide(136310-93-5) as a long-acting, specific, selective anticholinergic drugs, it selectively M1, M2 receptor function, compared with the β2 agonist, the role of ease and lasting, side effects, is the cornerstone of ACOS treatment. Previous tiotropium was used in the long-term maintenance treatment of bronchospasm associated with COPD, but not in the treatment of asthma. In the decade of clinical use of tiotropium, tiotropium has been shown to be effective in the treatment of asthma, both in animal studies and in clinical settings, and to improve the efficacy of tiotropium in the treatment of bronchial asthma.

In this study, budesonide powder inhalation combined with tiotropium bromide(136310-93-5) powder inhalation in the treatment of ACOS patients, and with tiotropium alone, budesonide alone in the treatment of two groups of ACOS patients were compared. After treatment, FEV1 (L), FEV1 /FVC(%), IC /TLC(%) and RV /TLC(%) of the three groups were significantly improved compared with those before the treatment. The combination of tiotropium and budesonide, the improvement rate of FEV1 (L), FEV1 /FVC(%), (RV /TLC)(%) in group C was significantly higher than that of tiotropium (A) and budesonide inhalation (B). After treatment, the ACT scores of asthma patients in the three groups were higher than those before treatment, and the condition was improved. But tiotropium bromide(136310-93-5) combined with budesonide group than tiotropium alone, the treatment of budesonide alone with two groups of symptoms improved more significantly, the difference between groups was statistically significant (P <0.05), after treatment of three The CAT scores of patients were lower than those before treatment. However, tiotropium combined with budesonide (C) group compared with tiotropium alone, treatment with budesonide alone improved the symptoms of the two groups is more obvious. (P <0.05). There was no significant difference in the number of acute exacerbations among the three groups (P> 0.05), but there was no significant difference between the three groups (P> 0.05). There was no significant difference between the three groups in the number of acute exacerbations.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved